Genelux Corp (GNLX)

[stocktowatch]

$GNLX Genelux_Corp Corporation to Participate in a Fireside Chat with H.C. Wainwright
WESTLAKE VILLAGE, Calif., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and Chairman of the Board will participate in a virtual fireside chat with H.C. Wainwright & Co. on December 16, 2024.



https://finance.yahoo.com/news/genelux-corporation-participate-fireside-chat-120100563.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr

[stocktowatch]

$GNLX November 2024 Corporate Presentation

https://investors.genelux.com/static-files/cb26a67f-274b-49ab-84cc-de52b67c4118

[stocktowatch]

$GNLX NASDAQ Genelux 2024 Annual Stockholder Meeting

[TheFinalCD]

https://finviz.com/quote.ashx?t=GNLX&ty=c&ta=1&p=d

[stocksrising]

Any news for pop??
Found it….sorry, just saw


Genelux Corporation Announces
First Patient Dosed in Phase 2
Trial Evaluating Systemic
Therapy with Olvi-Vec in Non-Small Cell Lung Cancer
GlobeNewswire
- VIRO-25 trial to assess efficacy & safety of olvimulogene nanivacirepvec (Olvi-Vec) & platinum-
doublet + physician's choice of immune checkpoint inhibitor compared to docetaxel in recurrent non-small cell lung cancer-
- Trial represents second indication in the clinic for Olvi-Vec via systemic administration -
- Interim readout expected mid-2025 -
WESTLAKE VILLAGE, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) - Genelux Corporation (GNLX. NaE) , a late-stage clinical immuno-oncology company, today announced that the first patient has been dosed in the U.S.-based Phase 2 (VIRO-25) trial evaluating systemically delivered Olvi-Vec in patients with recurrent non-small cell lung cancer (NSCLC) who have failed frontline platinum and immune checkpoint inhibitor (ICI) therapies.

[stocktowatch]

$GNLX Trending up resistance in play https://schrts.co/nQTnXUut

[stocktowatch]

$GNLX On alert for News!? stay tuned..

[stocktowatch]

$GNLX Possible Breakout! announcements, and upcoming milestones in a fireside chat at the H.C. Wainwright Global Healthcare Conference, taking place September 9-11, 2024, in New York City, New York. The conversation with Emily Bodnar, Vice President, Equity Research and H.C. Wainwright Biotechnology Analyst, is scheduled to begin at 12:30 p.m. ET on Wednesday, September 11, 2024. A webcast link for the H.C. Wainwright Conference event will be available at https://journey.ct.events/view/d1ba765d-c21b-46c9-8197-e4dd858808f0. An archived replay will be available for approximately 90 days following the event on the company’s IR page.

https://finance.yahoo.com/news/genelux-corporation-present-h-c-200100800.html

[stocktowatch]

$GNLX 1 Month chart resistance in play https://schrts.co/BWBNmgEe

[stocktowatch]

$GNLX Fundamental breakout Volume recovery get in early for the big boom https://schrts.co/sGWIJqyY

[Monksdream]

GNLX under $3

[stocktowatch]

Is Genelux (NASDAQ: $GNLX) In A Good Position To Invest In Growth? https://finance.yahoo.com/news/genelux-nasdaq-gnlx-good-position-134334395.html

[stocktowatch]

$GNLX Technical chart
https://schrts.co/SjVYghqR

[stocktowatch]

$GNLX Website : https://genelux.com/

[Monksdream]

GNLX under $3

[stocktowatch]

$GNLX historical movement price and volume https://ih.advfn.com/stock-market/NASDAQ/genelux-GNLX/historical

[Monksdream]

GNLX new 52 week low

[Monksdream]

GNLX new 52 lo

[Monksdream]

GNLX new 52 lo

[MiamiGent]

GNLX Genelux gets fast track status for Olvi-Vec in ovarian cancer
Nov. 27, 2023 3:22 PM ET Genelux Corporation (GNLX) By: Val Brickates Kennedy, SA News Editor

https://stockcharts.com/h-sc/ui?s=GNLX

Genelux (NASDAQ:GNLX) said it has received fast-track status from the FDA for its Olvi-Vec program for the treatment of platinum resistant/refractory ovarian cancer.

The company is currently conducting a Phase 3 registrational study of the immunotherapy in combination with platinum-based chemotherapy in patients with platinum resistant/refractory ovarian cancer.